Share Prices & Company Research

Stockbroking

Physiomics

Current Price 1.70p Bid 1.60p Ask 1.80p Change 0.00%
Last Updated: 02/04/2020 15:49. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Financial Highlights Year Ended 30/06/2019

Revenue
£0.72m
Operating Profit/Loss
£-0.20m
Dividend yield (%)
n/a
Total dividend for year
n/ap
Dividend cover
n/a
P/E Ratio
n/a

Key Personnel

Christophe Chassagnole
Chief Operating Officer
Paul Harper
Chairman
James Simon Millen
Chief Executive Officer

Stock Details

EPIC
PYC
ISIN
GB00BDR6W943
Shares in Issue
71.91m
Market cap
£1.22m
Sector

Analyst Views (0)

Strong Buy
 
0%
Buy
 
0%
Hold
 
0%
Sell
 
0%
Strong Sell
 
0%
This information is provided by Web Financial Group (UK) Limited. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
1.70p
Bid Price
1.60p
Ask Price
1.80p
Volume
405,239
Change Today
0.00p
% Change Today
0.00%
Open
1.70p
Previous Close
1.70p
Intraday High
1.80p
Intraday Low
1.60p
52 Week High
4.10p
52 Week Low
1.35p
52 week high and low figures quoted above are calculated from intraday price data.

Physiomics News

Physiomics receives 'Connect' funding award from NIHR 10 Mar 2020 | 11:39 Physiomics H1 revenues on the rise 03 Mar 2020 | 13:58 Physiomics scores further project agreement with CellCentric 23 Dec 2019 | 09:19 Physiomics surges amid deepened Merck collaboration 20 Dec 2019 | 12:32 Physiomics finishes year in line with expectations 30 Jul 2019 | 15:09 Physiomics wins immune-oncology contract from Bicycle Therapeutics 28 Jun 2019 | 10:56 Physiomics narrows interim loss as revenue leaps 21 Feb 2019 | 13:44 Physiomics inks strategic deal with Medicines Discovery Catapult 03 Jan 2019 | 14:33 Physiomics collaboration with Merck to last another year 17 Dec 2018 | 15:00 Physiomics wins small contract with European biotech client 09 Aug 2018 | 14:58 Physiomics appoints biosimulation expert Claire Villette to technical team 02 Jul 2018 | 15:57 Physiomics anticipates 'materially reduced' loss 21 Jun 2018 | 09:24 Physiomics lands contract with UK-based biotech 26 Apr 2018 | 12:52 Physiomics completes Innovate UK oesophageal cancer project 12 Mar 2018 | 15:12 Physiomics narrows losses despite sliding revenues 19 Feb 2018 | 13:12 Physiomics shares jump as new 'virtual tumour' contract signed 09 Feb 2018 | 14:58 Physiomics wins major new pharma client 26 Jan 2018 | 16:45 Physiomics soars on winning multi-year Merck services agreement 28 Nov 2017 | 11:06 Physiomics losses widen as major contract awaited 16 Oct 2017 | 14:15 Physiomics presenting at BioTrinity 05 May 2017 | 13:34 Physiomics makes 'good progress' towards objectives 11 Jan 2017 | 16:31 Physiomics receives Innovate UK grant for cancer treatment project 06 Jan 2017 | 13:04 Physiomics raises £555,000 after shelving BioMoti acquisition 21 Sep 2016 | 12:06 James Millen takes the helm at Physiomics 18 Apr 2016 | 14:11 Physiomics wins cancer therapy deal 14 Aug 2014 | 15:42

Income Statement

Year End Date
30 Jun 2019
30 Jun 2018
 
£ (M)
£ (M)
Continuing Operations
Revenue
0.72
0.43
Operating Profit/Loss
-0.20
-0.26
Net Interest
n/a
n/a
Pre-Tax Profit
-0.20
-0.26
Profit After Tax from continuing operations
-0.10
-0.18
Discontinued Operations
Profit After Tax
n/a
n/a
Profit/Loss for the Year
-0.10
-0.18
Attributable to:
Equity Holders of Parent Company
-0.10
-0.18
Minority Interests
n/a
n/a
Total Dividend Paid
n/ap
n/ap
Retained Profit/(Loss) for the Financial Year
n/a
n/a

Earnings per Share

Year End Date
30 Jun 2019
30 Jun 2018
Basic
-14.00p
-31.00p
Diluted
-14.00p
-31.00p
Adjusted
-14.00p
-31.00p
Dividend per Share
n/ap
n/ap

Assets

Year End Date
30 Jun 2019
30 Jun 2018
 
£ (M)
£ (M)
Non-Current Assets
Property, Plant & Equipment
0.02
0.01
Intangible Assets
n/a
n/a
Investment Properties
n/a
n/a
Investments
n/a
n/a
Other Financial Assets
n/a
n/a
Other Non-Current Assets
n/a
n/a
Current Assets
Inventories
n/a
n/a
Trade & Other Receivables
0.27
0.24
Cash at Bank & In Hand
0.41
0.57
Current Asset Investments
n/a
n/a
Other Current Assets
n/a
n/a
Other Assets
n/a
n/a
Total Assets
0.69
0.82

Liabilities

Year End Date
30 Jun 2019
30 Jun 2018
 
£ (M)
£ (M)
Current Liabilities
Borrowings
n/a
n/a
Other Current Liabilities
0.09
0.13
Total Current Liabilities
0.09
0.13
Non-Current Liabilities
Borrowings
n/a
n/a
Provisions
n/a
n/a
Other Non-Current Liabilities
n/a
n/a
Total Non-Current Liabilities
n/a
n/a
Other Liabilities
n/a
n/a
Total Liabilities
0.09
0.13

Net Assets

Year End Date
30 Jun 2019
30 Jun 2018
 
£ (M)
£ (M)
Net Assets
0.61
0.69

Capital & Reserves

Year End Date
30 Jun 2019
30 Jun 2018
 
£ (M)
£ (M)
Share Capital
1.18
1.18
Share Premium Account
5.23
5.23
Other Reserves
0.19
0.17
Retained Earnings
-5.99
-5.89
Shareholders Funds
0.61
0.69
Minority Interests/Other Equity
n/a
n/a
Total Equity
0.61
0.69

Dividend History

Type
Ex-Dividend Date
Payment Date
Payment

Dividend Metrics

Year End Date
30 Jun 2019
30 Jun 2018
Dividend growth
n/a%
n/a%
Dividend yield
n/a%
n/a%
Dividend cover
n/a
n/a
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 26th March 2020
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.